Clinical trials
Completed Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
52 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 3 |
| 2007 | 1 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 7 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 52 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 8 |
| Amgen | 6 |
| Kiadis Pharma | 3 |
| University College, London | 3 |
| Amgen Research (Munich) GmbH | 2 |
| Bristol-Myers Squibb | 2 |
| Cancer Research Campaign Clinical Trials Centre | 2 |
| Great Ormond Street Hospital for Children NHS Foundation Trust | 2 |
| Janssen Research & Development, LLC | 2 |
| Pfizer | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 52 |
| Leukemia, Myeloid, Acute | 14 |
| Leukemia | 9 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 9 |
| Myelodysplastic Syndromes | 6 |
| Recurrence | 6 |
| Burkitt Lymphoma | 5 |
| Hematologic Neoplasms | 5 |
| Lymphoma, Non-Hodgkin | 5 |
| Neoplasms | 5 |
Trials
Showing 1 to 25 of 52. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.